The Onco Mentor

ودلوقتي ميعاد الفزورة الجديدة
🧠💥 The Onco Mentor — Chemo Challenge Riddle 💥🧠

A 58-year-old woman with metastatic breast cancer is receiving doxorubicin + cyclophosphamide (AC protocol).
After her 3rd cycle, she reports new shortness of breath, fatigue, and mild ankle swelling.
Physical exam: HR 96 bpm, BP 110/70 mmHg, mild bilateral ankle edema, no crackles in lungs.
Echocardiogram: LVEF dropped from baseline 62% to 45%.

❓ What is the most appropriate next step?

A) Continue AC protocol and repeat echo after next cycle
B) Stop doxorubicin, switch to a non-anthracycline regimen
C) Start high-dose steroids immediately
D) Add prophylactic antibiotics

💬 جاوبوا في الكومنتات — وهنزل الإجابة مع الشرح قريب 😉

:إجابة الفزورة الى فاتت
The correct answer ✅ is: A) Reduce paclitaxel dose in the next cycle

Explanation:

The patient has metastatic triple-negative breast cancer and is receiving carboplatin + paclitaxel.
She presents with numbness, tingling, difficulty buttoning her shirt, and decreased sensation → all of these indicate grade 2 chemotherapy-induced peripheral neuropathy (CIPN), which is most commonly caused by paclitaxel.

Management According to NCCN & ASCO Guidelines:

🔹 Grade 1 CIPN:

Continue the same dose and monitor.

🔹 Grade 2 CIPN (as in this case):

Reduce paclitaxel dose in the next cycle

OR delay the next dose if symptoms are severe.

🔹 Grade 3 or 4 CIPN:

Discontinue paclitaxel permanently or switch to an alternative regimen.

🧠💥 The Onco Mentor — Chemo Puzzle Challenge 💥🧠

A 54-year-old woman with metastatic triple-negative breast cancer is receiving carboplatin + paclitaxel every 3 weeks.
Before cycle 3, she reports numbness and tingling in both hands and feet, with difficulty buttoning her shirt.
On exam, there is decreased sensation to light touch and vibration in a stocking-glove distribution.

❓According to standard oncology guidelines, what is the most appropriate immediate management?

A) Reduce paclitaxel dose in next cycle
B) Stop carboplatin permanently
C) Add pyridoxine (vitamin B6)
D) Continue same doses and monitor

💬 حط إجابتك في الكومنتات — الإجابة الصحيحة مع الشرح هتنزل قريب 😏

الى فاز معانا فى فزورة امبارح د. نوران و د .فتح الله
الإجابة الصح هنا هي B) Start infliximab (anti-TNF) ✅
:التفسير

المريض على nivolumab → مثبط PD-1 → ممكن يسبب immune-mediated colitis.

عنده Grade 3 diarrhea (شديد) واستبعدنا السبب المعدي.

بدأنا high-dose IV corticosteroids (methylprednisolone 1–2 mg/kg/day)، لكن مفيش تحسن بعد 72 ساعة → هذا يعني steroid-refractory colitis.

البروتوكولات (ASCO, ESMO, NCCN) تقول: في الحالة دي نوقف العلاج المناعي، ونبدأ infliximab 5 mg/kg IV كخط ثاني (ما عدا لو فيه perforation أو sepsis أو suspect TB).

⚠️ ملاحظات مهمة:

Loperamide (اختيار A) ممنوع في colitis المناعية الشديدة لأنه ممكن يخفي الأعراض ويزيد الخطر.

Switch إلى ipilimumab (C) غلط، لأنه برضو علاج مناعي لكن أكثر خطورة على القولون.

Antibiotics (D) مش indicated إلا لو فيه دليل على عدوى.

مستعدين للفزورة الجديدة ؟؟؟🤔🤔
🧠💥 The Onco Mentor — Advanced Protocol Riddle 💥🧠

A 62-year-old patient with metastatic melanoma is receiving nivolumab (a PD-1 inhibitor).
After 6 weeks he develops severe (grade 3) watery diarrhea with cramping and >7 stools/day, and infectious causes were excluded. He is started on high-dose IV corticosteroids but symptoms persist after 72 hours.

❓According to common immunotherapy toxicity protocols, what is the most appropriate next step?

A) Add loperamide and continue steroids
B) Start infliximab (anti-TNF)
C) Switch to ipilimumab (CTLA-4 inhibitor) instead
D) Start broad-spectrum antibiotics

💬 Drop your guesses in the comments — I’ll post the correct answer + brief explanation when you want.

إجابة اخر فزورة 💡
FLOT protocol
📌 Fluorouracil + Leucovorin + Oxaliplatin + Docetaxel

🧪 بيُستخدم قبل وبعد الجراحة لتحسين فرص السيطرة على المرض وزيادة معدل النجاة.

ودلوقتي ميعاد الفزورة الجديدة جاهزين 💪💪💪

اخر فزورة الى جاوبها صح Asmaa Elhussiney Mohamed Ezzat برافو يا دكاترة 👏👏👏
الإجابة الصحيحة:
B) MVAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin)

Explanation :

For muscle-invasive bladder cancer (urothelial carcinoma) with good kidney function,
neoadjuvant cisplatin-based chemotherapy is the standard of care before radical cystectomy.

Dose-dense MVAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin)
or

Gemcitabine + Cisplatin (GC)

are the main regimens.
However, MVAC (especially the dose-dense version) remains the classic gold standard with the strongest evidence for neoadjuvant use, particularly in fit patients.

Carboplatin is not recommended as a substitute for cisplatin in this setting because it’s less effective.

فزورة النهاردة 🧐🧐🤔🤔
🧠 Onco Protocol Riddle – Bladder Cancer Edition

A 65-year-old patient has muscle-invasive urothelial carcinoma of the bladder (MIBC) and normal kidney function.
He is planned for neoadjuvant chemotherapy before radical cystectomy.

❓Which chemotherapy regimen is considered the standard of care in this setting?

A) Gemcitabine + Cisplatin (GC)
B) MVAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin)
C) FOLFOX
D) Carboplatin + Paclitaxel

إجابة فزورة امبارح والى كسب معانا فيها Walaa Khalid Amira Aphnci ود فتح الله برافو يا دكاترة👏👏👏👏

B) Vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE

Explanation :

For localized Ewing sarcoma, the international standard first-line regimen is:

VDC/IE

VDC: Vincristine + Doxorubicin + Cyclophosphamide

alternated with

IE: Ifosfamide + Etoposide

This alternating schedule is given before and after local control (surgery and/or radiotherapy).

MAP (methotrexate/doxorubicin/cisplatin) is for osteosarcoma, not Ewing.

Gemcitabine/docetaxel is for relapsed soft tissue sarcoma.

FOLFIRINOX is for pancreatic cancer.

ودلوقتي فزورتنا الجديدة 🧐🧐🧐🤔🤔🤔🤔